| Title: | Isis Pharmaceuticals Conference Call to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship. Summary |
| Price: | $54.00 |
| Publication Date: | Jul 01, 2008 |
| Source: | Thomson StreetEvents |
| Report Type: | Brief |
| Abstract: | Edited Brief of ISIS conference call or presentation, 1-Jul-08 10:00am ET |
| Brief Excerpt: | ...On ##/##/##, ISIS announced that Abbott has completed the second $#m investment in Ibis, bringing total Abbott investment to $##m and increasing Abbott's ownership of Ibis to ##.#%. On ##/##/##, Co.'s partners ATL and TEVA announced the results of a Phase II study on TV#### in which TV#### demonstrated a medium reduction of ##.#% in cumulative number of new active lesions over the three-month period. ... |
| Word Count: | 5154 |
| Length: | 12 Pages |
| Ticker: | ISIS |
| Time: | 10:00am ET |
| Related Report(s): | |
| Format: |
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?